LCTX
Lineage Cell Therapeutics Inc
0.9476$
+1.0%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -404.3% | -288.3% | -400.5% | -367.6% | -153.1% | -221.3% | -325.3% | -200.3% | -98.2% | -73.8% | -468.3% | -677.6% | -182.0% | |
| 14.1% | 8.4% | 12.1% | 10.1% | 3.7% | 5.3% | 10.9% | 6.2% | 4.8% | 2.8% | 10.9% | 17.5% | 5.6% | |
| 101.8% | 50.8% | 80.5% | 90.1% | 35.2% | 45.9% | 81.0% | 44.8% | 32.6% | 16.6% | 67.9% | 149.8% | 38.8% | |
| -10.8% | -58.8% | -64.3% | -78.7% | -98.2% | -105.2% | -17.8% | -85.1% | -42.7% | 1.3% | -122.8% | -34.2% | -30.4% | |
| 11.2% | 4.4% | 2.6% | 3.6% | 3.0% | 12.7% | 6.5% | 0.5% | 0.3% | 1.7% | 3.2% | 5.1% | 1.8% | |
| 170.3% | 466.6% | -2.6% | -624.5% | 102.9% | 91.9% | 126.7% | -0.5% | -0.3% | -232.1% | -134.8% | 370.4% | -104.8% | |
| 0.0% | -9.5% | -1.6% | 0.0% | 0.6% | 0.0% | -1.0% | 0.0% | 0.0% | 0.0% | -2.3% | 0.0% | -0.3% | |
| – | – | – | – | -0.3% | -0.5% | -0.9% | -0.5% | -0.4% | -0.2% | -0.8% | -0.8% | -0.4% | |
| 64.8% | -0.6% | 971.0% | 7.5% | -0.1% | 757.8% | 335.8% | -11.1% | 49.8% | 308.4% | 322.4% | 417.8% | 246.4% | |
| -196.5% | 191.2% | 563.0% | -990.9% | -49.3% | 629.3% | 132.4% | -201.3% | -48.8% | 5.3% | -281.3% | 132.5% | -37.4% | |
| -415.4% | -292.6% | -403.1% | -371.2% | -156.1% | -234.0% | -331.8% | -200.8% | -98.6% | -75.5% | -471.5% | -672.5% | -183.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.